The ALS Association, together with partner Prize4Life, has announced the First Phase winners of The ALS Assistive Technology Challenge, which now enters its Prize Phase, where $400,000 will be awarded for the development of flexible, accessible technology to help people with amyotrophic lateral sclerosis (ALS) communicate better.
Because most symptoms of ALS are related to muscle activity, many people don’t realize the underlying cause: damage to the nerve cells. As ALS progresses, a few patients develop some level of cognitive impairment.
Matt Belina, US Navy pilot was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012. He and his wife are now actively trying to fight the barriers the FDA’s lack of approvals raise and prevent him from having access to experimental drugs he believes might save his life. Learn more…
German researchers have identified a new gene — called NEK1 — that appears to be responsible for familial amyotrophic lateral sclerosis (ALS). Loss of function mutations in the gene were more common in ALS patients than in healthy controls, according to findings published in the journal Brain. Familial ALS…
Jen and Pat Quinn, alumni from Iona College, were distinguished during the halftime at the Iona College Men’s basketball game versus Quinnipiac for their fight against amyotrophic lateral sclerosis (ALS). Video by SALRADIO. Learn more about ALS here: https://bit.ly/1RmVMwo…
In this video by ALS Society of Canada, meet Dr. Michael Strong, a pioneer in ALS research with more than 20 years’ experience. Watch him comment on where your donated dollars go in research and the achievements of his lab at Western University. Learn more about ALS…
OptiKey is a free, assistive on-screen keyboard software for computers on the Windows operating system. It is designed to be used with a low cost eye-tracking device to enable speech and keyboard and mouse control to people with motor and speech limitations, such as amyotrophic lateral sclerosis (ALS) or…
Last week’s hot topic on ALS was an article titled Biohaven’s ALS Drug Candidate BHV-0223 Receives Positive FDA Feedback written by Magdalena Kegel. The article is focused on the recently announcement that Portage Biotech and Biohaven Pharmaceuticals have received positive feedback from the U.S.
https://www.youtube.com/watch?v=iGZxxppCVbM In this video by the Motor Neurone Disease Association, meet Alistair the Optimist. Learn more about ALS here: https://bit.ly/ALSNewsToday…
Motor neurodegeneration in amyotrophic lateral sclerosis (ALS) can begin in axons at neuromuscular junctions and later spread to the cell body in the spinal cord, in a phenomenon known as the “dying back” hypothesis. Proteins involved in axonal regeneration may, for this reason, represent a potential therapeutic target in ALS. A research team from Germany found…
Get regular updates to your inbox.